Remdesivir–ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2020.12.23.424232: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2. VERO E6suggested: NoneSoftware and Algorithms Sentences Resources VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS … SciScore for 10.1101/2020.12.23.424232: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2. VERO E6suggested: NoneSoftware and Algorithms Sentences Resources VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2. Gibcosuggested: NoneResults from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-